EMEDZ.NET

Disclaimer Notice:

Dear Readers! I started this blog when my daughter was in the NICU. She had ventriculitis. Her CSF report grew E.coli. But, she was injected Teicoplanin directly into her brain. The doctors made two errors here:

Teicoplanin is for gram-positive bacteria only. It does not treat E.coli.
Teicoplanin is not for intraventricular use. The manufacturer strongly discourage injecting Teicoplanin into the brain.

My daughter bled into the brain. She lived for another two years and ultimately died.

The information provided on Emedz.net is for doctors and pharmacists only to manage their patients in the best way and avoid medications-related errors.

Still, for the general population, this should not be considered professional medical advice or a substitute for consultation with a licensed healthcare provider. The content on this blog is not intended to diagnose, treat, cure, or prevent any disease or health condition.

Always seek the advice of a qualified healthcare professional before making any changes to your diet, exercise routine, medication, or any other aspect of your healthcare. We strongly discourage self-medication and self-treatment.

Even though the primary author of emedz.net is an experienced health professional, the blog is not intended to replace medical advice sought at the Doctor’s Clinic.

The authors share personal experiences, research findings, and general knowledge about health and wellness and medications-related topics.

However, individual health situations vary, and what works for one person may not work for another. It's important to consult with a healthcare provider for personalized guidance.

We strive to provide accurate and up-to-date information, but medical knowledge is constantly evolving. Therefore, we do not guarantee the accuracy, completeness, or timeliness of the information presented in this blog.

Emedz.net is not an online pharmacy:

Online pharmacies sell medicines and pharmaceutical products. EMEDZ.net is intended to provide drug-related information to pharmacists and physicians. It is intended to provide authentic information about medicines so as to prevent errors related to prescriptions.

We do not sell medicines, so please don’t ask for them.

We are not affiliated with any pharmaceutical companies:

Emedz.net has no affiliation with any pharmaceutical companies. We do not promote any product. Sometimes brand names are also mentioned in the title of the page, but that is what is called a “Featured Image”. It has nothing to do with selling or promoting that brand. Just to make things easier, generic and brands are mentioned in the blog.

Emedz.net may contain links to external websites or resources for your convenience. We do not endorse or take responsibility for the content of these external sites.

In no event shall Emedz.net, its authors, contributors, or any related parties be liable for any damages or consequences arising from the use of the information provided on this blog.

By using Emedz.net, you acknowledge and agree to this disclaimer and our Terms of Use. If you do not agree with this disclaimer or our Terms of Use, we advise you to refrain from using our website.

Remember, your health is a valuable asset, and decisions about your health should always be made in consultation with a qualified healthcare professional.

Does Entyvio hcp (Vedolizumab) cause hair loss?

Entyvio hcp (Vedolizumab) is a humanized monoclonal antibody that stops the migration of memory T-lymphocytes across the endothelium into inflamed gastrointestinal parenchymal tissue by binding to the alpha-4 beta-7 integrin. This step is considered as the hallmark of inflammation in IBDs (inflammatory bowel diseases). It is usually administered at a dose of 300 mg as an intravenous infusion over 30 minutes in patients with moderately to severely active ulcerative colitis and Crohn's colitis who have an inadequate response to TNF inhibitors (e.g. Certolizumab and infliximab) and other immunomodulators.

Serious Side effects of Entyvio hcp:

Like most other biologic agents, Entyvio hcp (Vedolizumab) is associated with some serious side effects.

Most of the biologic agents including Entyvio (vedolizumab) have one or more of the following serious side effects:

Serious infusion-related allergic reactions,
Reactivation of serious infections like tuberculosis, fungal, bacterial, and viral infections.
Neurological side effects such as headache and progressive multifocal leukoencephalopathy.
Liver injury

Regarding the negative experiences of the use of biologics in patients with inflammatory bowel diseases, most patients showed their concerns for the following adverse events:

Increased risk of cancers
Safety of the drugs in pregnancy
Immune suppressant effects
Fatigue
Rashes
Skin lesions
infections
headache, and
hair loss

Hair loss, as a side effect of Entyvio hcp (vedolizumab), has not been mentioned in the manufacturer's labeling.

A study by Joseph Meserve et al titled "Retrospective Analysis of Safety of Vedolizumab in Patients With Inflammatory Bowel Diseases" evaluated more than 1000 patients for safety and adverse drug reactions. Out of a total of 1080 patients, only one patient reported hair loss as a side effect. Compared to Entyvio (vedolizumab), azathioprine and mercaptopurine are more likely to cause severe hair loss (A Phase 1, Multiple‐Dose Study of Vedolizumab in Japanese Patients With Ulcerative Colitis)

Most other studies have not reported hair loss as a side effect of the Entyvio. However, individuals have reported hair loss with the use of Entyvio.

Two patients reported hair loss while using Entyvio. One patient reported marked hair loss which the doctor thought was a consequence of disease severity.

The same patient had intestinal resection which might have led to decreased absorption of certain vitamins such as folic acid, biotin, and vitamin B12.

Folic acid, vitamin C, Biotin, and Vitamin B12 are important for hair growth.

The other patient reported thinning of hair, dryness, and brittle hair with Entyvio use but hair loss was not the primary complaint.

Skin manifestations of inflammatory bowel diseases:

Skin manifestations are among the common extraintestinal manifestations of inflammatory bowel diseases. Common skin manifestations of IBDs include:

Erythema nodosum

[caption id="attachment_10555" align="aligncenter" width="600"]

erythema nodosum[/caption]

Pyoderma gangrenosum

Sweet syndrome
Necrotizing cutaneous vasculitis
Psoriasis
Epidermolysis bullosa acquisita
Ulcerating skin nodules termed as metastatic Crohn's disease
Increased risk of skin cancers

In conclusion:

Most studies have not reported hair loss as a side effect of Entyvio (vedolizumab). However, rare individual patients have reported hair loss as a side effect.